Dyadic International Q1 net loss narrows

Dyadic International

13/05/2026 21:18

Overview

US biotechnology firm's Q1 revenue rose 182% yr/yr, driven by R&D, grant, and milestone revenue

Net loss narrowed to $1.9 mln from $2.0 mln a year ago

Company expanded commercial launches and partnerships in cultivated meat, life sciences, and nutrition markets

Outlook

Company did not provide specific financial guidance for the current quarter or full year

Result Drivers

R&D AND GRANT REVENUE - Co said revenue growth was driven by higher research and development revenue, primarily related to the Proliant agreement, and increased grant revenue from CEPI and Gates Foundation activities

MILESTONE PAYMENTS - License and milestone revenue rose due to achieving a contract milestone under the Inzymes agreement

COMMERCIAL LAUNCHES AND PARTNERSHIPS - Co cited commercial launches of recombinant proteins and expanded partnerships, including with Proliant, Fermbox Bio, and IBT Bioservices, as supporting revenue growth and broader market reach

Company press release: ID:nGNX6nKRnt

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 EPS
-$0.05


Analyst Coverage

The one available analyst rating on the shares is "buy"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Dyadic International Inc is $6.00, about 730.1% above its May 12 closing price of $0.72

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)